News About: Pharm. Industry
Eisai acquires domestic approval of ‘Lenvima,’ thyroid cancer treatment
Eisai Korea(President Hong-byung Ko) announced Eisai, a global pharmaceutical company, has acquired approval for its newly developed antibiotics, ‘Lenvima Cap(generic name: lenvatinib),’ as treatment of progressive di...
19 healthcare and biopharmaceutical businessmen participate the economic mission
19 businessmen in the healthcare and biopharmaceutical industries, such as President Jang-han Lee of Chong Kun Dang, President Eun-sun Kim of Boryung Pharm and CEO Kwan-soon Lee of Hanmi Pharm, will accompany Presiden...
Over-evaluated medical device companies with 4.5 PBR
It was known that the price-to-book ratio(PBR) of domestic medical device companies is estimated at 4.5 in average, becoming much higher than the ratio of the pharmaceutical industry.
According to the analysis result...
What will be main domestic pharmaceutical products of Amgen soon to be launched?
Domestic products of Amgen which will be officially launched have been visualized.
According to the industry concerned on the 12th, the Korean branch of Amgen turned in applications of ‘Kyprolis(carfilzomib),’ a mult...
‘Is there a clear way to eradicate illegal rebates?’ said the pharmaceutical association and industry
Is there a strong and clear way to solve this?
The pharmaceutical association and the pharmaceutical industry have been concerned. It was observed excessive competition for generic products that are already or expect...
Janssen vs Otsuka expects domestic competition for long-acting schizophrenia drugss
In the schizophrenia treatment market, competition to introduce long-acting injections has become active.
Leading pharmaceutical companies in the field, Janssen and Otsuka, have released follow-up products in series....
Poor personnel pool incited serial movement of OTC PMs
The insufficient personnel pool of the OTC drug market has generalized serial movement of existing product managers(PM).
One of common opinions is that the phenomenon is inevitable in the insufficient circumstance of...
‘Baraclude’ won the lawsuit of injunction in patent infringement against Dong-ABMS Pharmaceutical Korea(President Hye-sun Park) announced on the 7th the company has won a lawsuit of injunction in patent infringement against Dong-A ST over ‘Baraclude® (gene...
|
Boryung Pharm succeeded in avoidance of ‘Alimta Inj’ patentOver the hydrate patent(Korea Patent Registration No. 0744917) related to the main substance of the recent lung cancer treatment ‘Alimta(generic name: pemetrexed disodium heptah...
|
MFDS to prevent fiercer Cialis generic competitionAs the market of Cialis, an erectile dysfunction treatment, is getting fiercer due to its patent expiration, the Ministry of Food and Drug Safety has begun to control the trend....
|
